Auris Medical Makes Key Progress With Midstage Vertigo Trial

Health and Healthcare

Published: September 3, 2020 11:10 am

On Thursday, Auris Medical Holding Ltd. (NASDAQ: EARS) reported topline data from its Phase 2 Travers trial with intranasal betahistine (AM-125) in vertigo. These results sent shares higher in morning trading.

Overall, the interim analysis of the topline data was positive, but it was only based on Part A of the trial that has 33 patients enrolled. These patients are suffering from vertigo following neurosurgery.

The study demonstrated a dose-dependent improvement in balance as well as good safety and tolerability of ascending doses of AM-125. At the highest dose, AM-125-treated patients improved their performance of the “Tandem Romberg” and the “Standing on Foam” balance tests from baseline to 14 days post-surgery (primary endpoint) on average 1.9 to 2.4 times more than placebo-treated patients.

In contrast to placebo, the improvement from baseline was statistically significant for AM-125. These positive results were supported by similar improvements in additional efficacy measures, including additional objective as well as clinician- and patient-reported outcomes.

Based on the results from the interim analysis, the two highest doses, 10 and 20 mg, were selected by the company to be tested against placebo in 72 patients in Part B of the trial.

Also, the improvement in the “Standing on Foam” test will become the sole primary efficacy endpoint. This test measures how long patients are able to maintain balance on a foam mat with their eyes closed, relying primarily on vestibular input from their inner ears.

The improvement in the more challenging “Tandem Romberg” test, which is performed with eyes closed and the two feet aligned one after the other, will become the key secondary efficacy endpoint.

Auris Medical stock traded up about 28% on Thursday, at $1.07 in a 52-week range of $0.65 to $3.20. The consensus price target is $14.95.

24/7 Wall St.
BofA Securities Makes Big Fall Changes to High Quality & Dividend Yield Portfolio

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!